Page 1 - Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

CUAJ – Consensus Statement Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus
statement: Management of unresectable locally advanced and metastatic urothelial
carcinoma

1,2
1,3
Mark Warren, MBBS, FRACP ; Michael Kolinsky, MD, FRCPC ; Christina M. Canil, MD,
8
4,5
6,7
FRCPC ; Piotr Czaykowski, MD, MSc, FRCPC ; Srikala S. Sridhar, MD,FRCPC ; Peter C.
10
9
Black, MD, FRCSC, FACS ; Christopher M. Booth, MD, FRCPC ; Wassim Kassouf, MD, CM,
13
11
FRCSC ; Libni Eapen, MD, FRCPC 5,12 ; Som D. Mukherjee, MD, MSc, FRCPC ; Normand
16
14
15
Blais, MD, MSc, FRCPC ; Bernhard J. Eigl, MD, FRCPC ; Eric Winquist, MD, MSc ;
1,3
1,3
Naveen S. Basappa, MD, FRCPC ; Scott A. North, MD, FRCPC ; on behalf of GUMOC
1 Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada; Cancer Centre, Bendigo
2
3
4
Health, Bendigo, Australia; University of Alberta, Edmonton, AB, Canada; The Ottawa Hospital Cancer Centre,
6
5
Ottawa, ON Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada; Cancer Care Manitoba, Winnipeg,
MB, Canada; University of Manitoba, Winnipeg, MB, Canada; Division of Hematology and Medical Oncology,
8
7
Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON,
9
Canada; Department of Urological Sciences, University of British Columbia, Vancouver, BC,
10
11
Canada; Department of Oncology, Queen’s University, Kingston, ON, Canada; Department of Surgery, McGill
12
University Health Centre, Montreal, QC, Canada; Division of Radiation Oncology, University of Ottawa, ON,
13
14
Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Division of Medical Oncology/Hematology, Centre
15
Hospitalier de l’ Université de Montréal, , Montréal, Quebec, Canada; BC Cancer, Vancouver, BC, Canada,
16
University of British Columbia, BC, Canada; Division of Medical Oncology, Western University and London
Health Sciences Centre, London, ON, Canada

Cite as: Can Urol Assoc J 2019 April 26; Epub ahead of print.
http://dx.doi.org/10.5489/cuaj.6015

Published online April 26, 2019

***

Introduction
th
In Canada, bladder cancer ranks as the 5 most common cancer with an estimated 8900 new
1
cases and 2400 deaths in 2018. Approximately 15% of patients have locally advanced or
metastatic disease at presentation. A further 40 – 50% of those with muscle invasive early stage
disease will relapse after initial treatment. The majority of patients with advanced stage disease
will succumb to their disease. Cancers of the ureter, renal pelvis and proximal urethra constitute
approximately 5-10% of cases of urothelial carcinoma and are treated with similar systemic
therapy as bladder cancer.
GUMOC (Genitourinary Medical Oncologists of Canada) is comprised of Canadian
Medical Oncologists who specialize in the treatment of genitourinary cancers. With recent